SYDNEY, Australia – 2 April 2019 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.
The poster (abstract number 8249) was presented by Professor Ursula Wiedermann from the Medical University Vienna, the lead-inventor of the HER-Vaxx cancer vaccine and member of Imugene’s Scientific Advisory Board, together with a well known research team at the Medical University Vienna.
Imugene Managing Director and Chief Executive Officer Leslie Chong said, “We are encouraged by the overall positive data from the Phase Ib trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”
Highlights of Professor Wiedermann’s presentation included:
A Phase 2 HER-Vaxx study was initiated in March 2019.
The abstract presentation was entitled ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach”, and was authored by Professor Wiedermann and researchers at the Medical University of Vienna in Austria and Imugene Limited.
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and now in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.
The full presentation is available on the Imugene website: www.imugene.com/publications
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Find out more at www.imugene.com.
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
Issued for and on behalf of Imugene by Instinctif Partners.
For more information please contact: firstname.lastname@example.org